EXHIBIT GUIDE

Georgia Association of Pathology

VIRTUAL 2020 ANNUAL MEETING

November 7, 2020

©2020 AstraZeneca. All rights reserved. US-40909 6/20

BRCA, breast cancer susceptibility gene; PARP, poly ADP-ribose polymerase.

References: 1. Frey MK et al. Gynecol Oncol Res Pract. 2017;4:4. 2. Pennington KP et al. Clin Cancer Res. 2013;20(3):764-775. 3. Konstantinopoulos PA et al. Cancer Discov. 2015;5(11):1137-1154. 4. Ledermann JA et al. Eur J Cancer. 2016;60:49-58. 5. Watkins JA et al. Breast Cancer Res. 2014;16(3):211. 6. Cheema PK et al. J Oncol Pract. 2017;13(2):e130-e138. 7. Hoskins PJ et al. CA Cancer J Clin. 2017;67(6):493-506. 8. Sundin T. Med Lab Manag. 2019;8(11):6.

1 in 2 women with HRD-positive tumors do not have a BRCA1/2 mutation1-4

Homologous recombination repair defi ciency (HRD) testing identifi es tumor characteristics —beyond BRCA1/2 mutation—that make it sensitive to PARP inhibition.1,5

Personalized medicine begins with personalized pathology. Discuss establishing a testing protocol for HRD in ovarian cancer with the multidisciplinary team at your institution.6-8

Learn more at testforHRD.com

In advanced ovarian cancer,

If you’re not testing for HRD, you’re not seeing the whole picture

HEADER

3 GAP 2020 Annual Meeting

PROGRAM SCHEDULEPlease note, all times are listed in Eastern Time

SATURDAY, NOVEMBER 07, 2020GENERAL SESSION

8:30 a.m. - 8:45 a.m. Welcome and Opening Remarks President: Matthew Fries, MD

8:45 a.m. - 9:15 a.m. Barrett’s Esophagus: Old and New Speaker: Alyssa M. Krasinskas, MD

9:15 a.m. - 9:45 a.m. Problematic Colorectal Polyps Speaker: Amanda Barrett, MD

9:45 a.m. - 10:35 a.m. Industry Symposium

10:35 a.m. - 11:05 a.m. Mucinous Neoplasms of the Appendix Speaker: Zaid Mahdi, MD

11:05 a.m. - 11:35 a.m. Neuroendocrine Tumors Speaker: Michelle Reid, MD, MS

11:35 a.m. - 12:20 p.m. Keynote Lecture: Impact of Molecular Analysis on the Diagnosis of Liver Tumors: Another Tool in our Arsenal Speaker: Sanjay Kakar

12:20 p.m. - 12:35 p.m. GAP Annual Business Meeting

12:35 p.m. - 12:45 p.m. CME Break

12:45 p.m. - 1:30 p.m. Legislative & Advocacy Update Speaker: Patrick Godbey, MD

1:30 p.m. - 2:00 p.m. Molecular Testing of COVID-19: EffectiveOptimizationofSARS- CoV-2 Laboratory Testing Variables in an Era of Supply Chain Constraints Speaker: Ravindra Kolhe, MD, PhD, FCAP

2:00 p.m. - 2:30 p.m. Coagulation and Peripheral Blood Smear Findings in COVID19 Speakers: Cheryl Maier Deniz Peker, MD

2:30 p.m. - 3:20 p.m. Industry Symposium

3:20 p.m. - 3:50 p.m. Autopsy Findings in COVID-19 Speaker: Mario Mosunjac

3:50 p.m. - 4:50 p.m. Panel Discussion of UndifferentiatedNeoplasms/ Malignant Neoplasms of Unknown Primary Panelists: George Deeb Lara Harik, MD Sravan Kavuri, MD Uma Krishnamurti, MD, PhD Amyn Rojiani, MD, PhD, CPE Natasha M. Savage, MD, FCAP

4:50 p.m. - 5:30 p.m. Resident Case Presentations Speakers: Caroline Bsirini, MD Alexander Dent Saleh Heneidi, MD Dorian Willhite

5:30 p.m. - 6:30 p.m. Virtual Social Hour and Townhall (BYOB)

HEADER

4 GAP 2020 Annual Meeting

INDUSTRY SYMPOSIUMSATURDAY, NOVEMBER 7, 2020

9:45 a.m. - 10:35 a.m.

Cancer,GenesandComprehensiveGenomicProfilingJeffrey S Ross, MDMedical Director, Foundation Medicine

Sponsored by: Foundation Medicine

2:30 p.m. - 3:20 p.m.

Molecular Testing Strategies in Lung and Ovarian CancerDr. John LongshoreDirectory, Molecular Pathology

Sponsored by: AstraZeneca

HEADER

5 GAP 2020 Annual Meeting

SPECIAL THANKS TO OUR INDUSTRY SUPPORTERS

GOLD LEVEL

*Medicare and Medicare Advantage members have coverage of FoundationOne CDx in accordance with the Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) criteria.

FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com.

© 2020 Foundation Medicine, Inc. | MKT-0287-02

ONE FDA-APPROVED TEST ANALYZES 324 GENESOur comprehensive genomic profiling revolves around your patient.

As part of our proven portfolio of tests and services, FoundationOne CDx analyzes all recommended genomic biomarkers for solid tumors, including companion diagnostic

indications with direct paths to therapy. With Medicare coverage for qualifying patients,* this one test can help guide therapy selection and clinical trial options for more patients.

Learn about the power of one at foundationmedicine.com/f1cdx

FISH

CYTOGENETICS

GENOMICS

CDX & IVD

MULTIOMYX™

FLOW CYTOMETRY

ANATOMICPATHOLOGY

NeoGenomics Cancer diagnosticsthat bridge oncology, pathology and research for complete patient care.

NeoGenomics is proud to be a Premier Level Partnerat GAP 2020 Virtual Meeting.

GEORGIA ASSOCIATION OF PATHOLOGY Two Woodfield Lake | 1100 E Woodfield Road, Suite 350 | Schaumburg, IL 60173

(847) 517-7225 | gap@weiser.com